aod9604 - 300mcg troche AOD 9604 Peptide Therapy AOD 9604 - PRAMAH /

AOD9604 represents part of a broader scientific effort to develop targeted therapies that can isolate beneficial effects of growth hormone while avoiding unwanted systemic effects, similar to the development of selective androgen receptor modulators (SARMs) or selective estrogen receptor modulators (SERMs) in other therapeutic areas

Findings suggest it may operate differently than growth hormone, particularly in relation to receptor interaction and lean body mass

Diabetes, Obesity and Metabolism

For stopping loss, finasteride and minoxidil are first-line

Difficulty swallowing or breathing (anaphylaxis) is also possible

CityHealth accepts most major insurance plans including Medi-Cal, Blue Cross, Aetna, Cigna, United Healthcare, and others